

(LQ 067)

FEBRUARY 2020

Sub. Code: 1404

D.M. - CLINICAL HAEMATOLOGY

Paper IV – RECENT ADVANCES IN HAEMATOLOGY

Q.P. Code: 161404

Time: Three Hours Maximum: 100 Marks

I. Elaborate on: $(2 \times 15 = 30)$

1. Discuss the recent changes in the WHO 2016 criteria for diagnosis of myeloproliferative neoplasms.

2. Discuss the diagnosis and relevance of Philadelphia like acute lymphoblastic leukemia. Also discuss potential strategies to treat these conditions.

II. Write notes on: $(10 \times 7 = 70)$

- 1. Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199.
- 2. Role of hypo-methylating agents in high risk young adults with acute myeloid leukemia.
- 3. Thrombopoeitin receptor agonists and aplastic anemia.
- 4. Liposomal CPX-351 in acute myeloid leukemia.
- 5. Targeting microenvironment in leukemia.
- 6. Artesunate in the management of cytomegalovirus infection.
- 7. Gene editing strategies.
- 8. Potential role of Pioglitazone in the management of chronic myeloid leukemia.
- 9. Potential role and rationale of IL2 in management of acute graft versus host disease.
- 10. Nontransplant therapy in aplastic anemia.
